Danley Dennis E
Department of Exploratory Medicinal Sciences, Pfizer Global Research and Development, Pfizer Inc., Groton, CT 06340, USA.
Acta Crystallogr D Biol Crystallogr. 2006 Jun;62(Pt 6):569-75. doi: 10.1107/S0907444906012601. Epub 2006 May 12.
The use of X-ray crystallography to derive three-dimensional structures for structure-aided drug design (SADD) is a common activity in drug discovery today. In this process, the structures of inhibitors or other ligands of interest complexed with their macromolecular target are solved and the structural information is used iteratively to design new molecules. The ability to form cocrystal complexes between a target protein and a ligand is essential to this process and therefore is of considerable interest to anyone practicing in this field. In the course of obtaining the necessary ligand-protein crystals, even with crystallization conditions well established for a protein of interest, obtaining co-structures with inhibitors either through cocrystallization or soaking is too often not successful. There are numerous potential reasons for this lack of success and this article outlines a number of possible factors that may be involved and discusses considerations that should be taken into account when designing successful experiments to obtain iterative costructures.
利用X射线晶体学推导三维结构用于结构辅助药物设计(SADD)是当今药物发现中的常见做法。在这个过程中,与感兴趣的大分子靶点复合的抑制剂或其他配体的结构得以解析,并且利用这些结构信息反复设计新分子。在靶点蛋白和配体之间形成共晶体复合物的能力对于这个过程至关重要,因此对于该领域的任何从业者来说都具有相当大的吸引力。在获取必要的配体-蛋白晶体的过程中,即使针对感兴趣的蛋白质已经很好地建立了结晶条件,但通过共结晶或浸泡获得与抑制剂的共结构往往并不成功。这种缺乏成功的原因有很多,本文概述了一些可能涉及的因素,并讨论了在设计成功的实验以获得反复的共结构时应考虑的事项。